14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today DVAX ranks #15338 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Dynavax Technologies Corporation Stock Forecast NASDAQ:DVAX

$13.17 (-10.41%)

Volume: 4M

Closed: Dec 03, 2021

Hollow Logo Score: -4.469

Dynavax Technologies Corporation Stock Forecast

$13.17 (-10.41%)

Volume: 4M

Closed: Dec 03, 2021

Score Hollow Logo -4.469
Which way will DVAX go? Request
Key Stats
P/E Ratio -40.57
Beta 2.14
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Dynavax Technologies Corporation stock currently holds an RSI14 at 16 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Big movements in Dynavax Technologies Corporation stock price on Friday moving 11.15% between high and low
(Updated on Dec 03, 2021)


Sell candidate since 2021-11-29 Loss -18.05%

The Dynavax Technologies Corporation stock price fell by -10.41% on the last day (Friday, 3rd Dec 2021) from $14.70 to $13.17. and has now fallen 4 days in a row. During the day the stock fluctuated 11.15% from a day low at $12.82 to a day high of $14.25. The price has fallen in 8 of the last 10 days and is down by -21.37% for this period. Volume has increased on the last day by 2 million shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 4 million shares were bought and sold for approximately $57.83 million.

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($13.25) are considered to be a "second chance" to get out. According to the fan-theory $5.81 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Dynavax Technologies Corporation stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $15.42 and $17.44. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, November 03, 2021, and so far it has fallen -37.11%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.43 between high and low, or 11.15%. For the last week, the stock has had a daily average volatility of 8.08%.

Dynavax Technologies Corporation is oversold on RSI14 (16). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Dynavax Technologies Corporation stock A Buy?

Dynavax Technologies Corporation holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.469

Predicted Opening Price for Dynavax Technologies Corporation of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$13.41 $13.17 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 01, 2021 "William Blair" gave "" rating for DVAX. The price target was changed from $16.84 to 12.3%.

Volatility and Risk
Daily Average Volatility: 8.08 %
Overall Risk: Very High High Medium Low Very Low
Volatility
8.08 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $14.74
Price: $13.17
No Support Found

DVAX Insider Trading Show all Trades

INSIDER POWER

0.897

Last 100 transactions
Buy: 7 074 537 | Sell: 7 886 268 (Shares)
Date Action Amount Person Type
Nov 17, 2021 Sell 53 431 Janssen Robert Stock Option (Right to Buy)
Nov 17, 2021 Sell 35 974 Janssen Robert Stock Option (Right to Buy)
Nov 17, 2021 Sell 53 431 Janssen Robert Common Stock
Nov 17, 2021 Buy 53 431 Janssen Robert Common Stock
Nov 16, 2021 Sell 35 974 Janssen Robert Common Stock
Show all Insider Trades
INSIDER POWER

0.897

Last 100 transactions
Buy: 7 074 537 | Sell: 7 886 268 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 14.84 12.71 %
14.30 8.56 %
13.96 6.00 %
Current price: 13.17
Support 12.87 -2.30 %
12.53 -4.86 %
11.98 -9.01 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 16.16 22.70 %
14.89 13.06 %
14.74 11.92 %
Current price 13.17
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Dynavax Technologies Corporation

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. Its development programs focuses on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company’s lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT